Camille Andre, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Staphylococcal Infections | 6 | 2024 | 1398 | 1.350 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 687 | 1.250 |
Why?
|
Eye Infections | 1 | 2022 | 65 | 0.800 |
Why?
|
Achromobacter | 1 | 2021 | 7 | 0.780 |
Why?
|
Conjunctivitis | 1 | 2022 | 158 | 0.750 |
Why?
|
Organ Preservation Solutions | 1 | 2021 | 98 | 0.740 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 247 | 0.710 |
Why?
|
Drug Contamination | 1 | 2021 | 147 | 0.700 |
Why?
|
Ophthalmic Solutions | 1 | 2021 | 316 | 0.690 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.670 |
Why?
|
Staphylococcus | 4 | 2024 | 154 | 0.660 |
Why?
|
Anti-Infective Agents | 1 | 2024 | 966 | 0.550 |
Why?
|
Microbial Sensitivity Tests | 5 | 2024 | 1873 | 0.490 |
Why?
|
Macrolides | 2 | 2024 | 202 | 0.400 |
Why?
|
Drug Resistance, Bacterial | 3 | 2024 | 1029 | 0.370 |
Why?
|
Anti-Bacterial Agents | 6 | 2024 | 7179 | 0.310 |
Why?
|
Staphylococcus aureus | 4 | 2024 | 1452 | 0.290 |
Why?
|
Streptococcus | 1 | 2024 | 197 | 0.230 |
Why?
|
Methicillin Resistance | 2 | 2022 | 198 | 0.220 |
Why?
|
Azithromycin | 1 | 2024 | 195 | 0.210 |
Why?
|
Fluoroquinolones | 1 | 2024 | 305 | 0.200 |
Why?
|
Bone Diseases, Infectious | 1 | 2021 | 18 | 0.200 |
Why?
|
Eye Banks | 1 | 2021 | 38 | 0.190 |
Why?
|
Vaccines, Conjugate | 1 | 2022 | 334 | 0.180 |
Why?
|
Keratoplasty, Penetrating | 1 | 2021 | 154 | 0.180 |
Why?
|
DNA, Ribosomal | 1 | 2021 | 291 | 0.180 |
Why?
|
Bacteriological Techniques | 1 | 2021 | 277 | 0.170 |
Why?
|
Vancomycin | 1 | 2022 | 500 | 0.170 |
Why?
|
Penicillin-Binding Proteins | 1 | 2019 | 138 | 0.160 |
Why?
|
Pneumococcal Vaccines | 1 | 2022 | 390 | 0.160 |
Why?
|
Tissue and Organ Harvesting | 1 | 2021 | 368 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 412 | 0.150 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 953 | 0.150 |
Why?
|
Joint Diseases | 1 | 2021 | 480 | 0.140 |
Why?
|
Streptococcus pneumoniae | 1 | 2022 | 712 | 0.140 |
Why?
|
Immunoassay | 1 | 2019 | 750 | 0.140 |
Why?
|
Tissue Donors | 1 | 2021 | 2232 | 0.100 |
Why?
|
RNA, Ribosomal, 23S | 1 | 2022 | 53 | 0.050 |
Why?
|
Staphylococcus epidermidis | 1 | 2022 | 119 | 0.050 |
Why?
|
Afghanistan | 1 | 2021 | 81 | 0.050 |
Why?
|
Humans | 8 | 2024 | 743521 | 0.050 |
Why?
|
Daptomycin | 1 | 2021 | 72 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
Clone Cells | 1 | 2022 | 1693 | 0.040 |
Why?
|
Virulence Factors | 1 | 2021 | 509 | 0.040 |
Why?
|
Lysosomes | 1 | 2021 | 896 | 0.030 |
Why?
|
Phylogeny | 1 | 2022 | 2796 | 0.030 |
Why?
|
Hospitals | 1 | 2022 | 3961 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19847 | 0.010 |
Why?
|